Follow-up on corrections·March 22, 2023

Licensing Program Analyst (LPA) Kelly Dulek conducted a case management-deficiencies visit at the facility today. The LPA arrived at 11:00AM and met with Executive Director (ED) Bradlee Foerschner. Entrance interview conducted. During today’s visit, LPA conducted a medication review with ED and the Medication Technician at 12:52PM. During the medication review, it was discovered that Resident #1 (R1)'s prescription Atorvastatin 40 mg was labeled as started 11/29/2022, originally contained 100 pills, but ED counted more than 100 pills in the bottle. MAR indicated this medication has been administered daily in March 2023. ED counted medications and verified that two (2) additional medications did not contain the amount indicated the bottles should contain, without documentation of exceptions. Medications for Resident #2 (R2) were also reviewed. R2's Atorvastatin 10mg was opened on 03/03/2023 and originally contained 30 doses. 21 doses remain, although 20 days have elapsed since 03/03/2023 and therefore only 10 doses should remain. R2's Trazodone 50mg was opened 03/02/2023 and originally contained 30 doses. 9 doses remain, although 10 should remain based on days elapsed since the date the medication was opened. Pursuant to Title 22 CA Code of Regulations, the following deficiency was cited (refer to LIC 809-D). As this is a repeat violation, a civil penalty was issued in the amount of $250. Exit interview conducted. A copy of the report and appeal rights were provided.